ArriVent BioPharma Inc. Common Stock (AVBP)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings and understandable economics. ArriVent has no revenue in any filed period; it is a clinical-stage cancer drug developer whose lead candidate, firmonertinib, remains in trials. The losses are widening: in fiscal 2025, the year ended 2025-12-31, net loss was $166.3 million, versus $80.5 million in fiscal 2024, the year ended 2024-12-31, and $69.3 million in fiscal 2023, the year ended 2023-12-31. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $49.9 million and diluted EPS was -$1.05. Trailing free cash flow is -$147.9 million, a FairStock calculation, and the FCF yield is -18.6%. The Piotroski F-Score is 2/9, the FairStock score is 20/100, and the P/E is -4.53. The debt-to-equity ratio is 0.00, and the Altman Z-Score is 16.42, both FairStock calculations, so leverage is not the immediate issue. Still, no moat exists yet; the entire value depends on clinical success and eventual commercialization. At $16.09 on 2026-10-13, the market cap is $793.4 million with a P/B of 2.12. Graham would demand a margin of safety in assets or earnings. Here there are no earnings, and book value is being consumed by cash burn. This is a speculative biotech, not a predictable compounder. I would need trial progress and a clearer path to revenue before assigning intrinsic value.

In plain English: ArriVent BioPharma is a clinical-stage cancer drug developer with no product sales yet. It is losing money and using cash to fund trials, and its losses have been growing. At $16.09 on 2026-10-13, the market value is about $793 million, but with no revenue or profits, the price looks speculative rather than clearly cheap or expensive based on current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer